Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma

References

• Siersema PD. Esophageal cancer. Gastroenterol Clin North Am. 2008;37(4):943–11. 10.1016/j.gtc.2008.09.012.
   PubMed Web of Science ®Google Scholar
• Hirano H, Kato K. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol. 2019;49(5):412–20. doi:10.1093/jjco/hyz034.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78. doi:10.1016/j.ejphar.2014.07.025.
   PubMed Web of Science ®Google Scholar
• Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy. Radiol Oncol. 2019;53(2):148–58. doi:10.2478/raon-2019-0018.
   PubMed Web of Science ®Google Scholar
• Abbaszadeh Z, Cesmeli S, Biray Avci C. Crucial players in glycolysis: cancer progress. Gene. 2020;726:144158. doi:10.1016/j.gene.2019.144158.
   PubMed Web of Science ®Google Scholar
• Akram M. Mini-review on glycolysis and cancer. J Cancer Educ. 2013;28(3):454–57. doi:10.1007/s13187-013-0486-9.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Enriquez S, Marin-Hernandez Á, Gallardo-Perez JC, Pacheco-Velazquez SC, Belmont-Diaz JA, Robledo-Cadena DX, Vargas-Navarro JL, Corona de la Peña NA, Saavedra E, Moreno-Sánchez R, et al. Transcriptional regulation of energy metabolism in cancer cells. Cells. 2019;8(10):1225. doi:10.3390/cells8101225.
   PubMed Web of Science ®Google Scholar
• Schwartz L, Supuran CT, Alfarouk KO. The Warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem. 2017;17(2):164–70. doi:10.2174/1871520616666161031143301.
   PubMed Web of Science ®Google Scholar
• Dai H, Sinclair DA, Ellis JL, Steegborn C. Sirtuin activators and inhibitors: promises, achievements, and challenges. Pharmacol Ther. 2018;188:140–54. doi:10.1016/j.pharmthera.2018.03.004.
   PubMed Web of Science ®Google Scholar
• Nikas IP, Paschou SA, Ryu HS. The role of nicotinamide in cancer chemoprevention and therapy. Biomolecules. 2020;10(3):477. doi:10.3390/biom10030477.
   PubMed Web of Science ®Google Scholar
• Yousafzai NA, Jin H, Ullah M, Wang X. Recent advances of SIRT1 and implications in chemotherapeutics resistance in cancer. Am J Cancer Res. 2021;11:5233–48.
   PubMed Web of Science ®Google Scholar
• Chen J, Cao L, Li Z, Li Y. SIRT1 promotes GLUT1 expression and bladder cancer progression via regulation of glucose uptake. Hum Cell. 2019;32(2):193–201. doi:10.1007/s13577-019-00237-5.
   PubMed Web of Science ®Google Scholar
• John S, Weiss JN, Ribalet B, Rodrigues-Lima F. Subcellular localization of hexokinases I and II directs the metabolic fate of glucose. PLOS ONE. 2011;6(3):e17674. doi:10.1371/journal.pone.0017674.
   PubMed Web of Science ®Google Scholar
• Roberts DJ, Miyamoto S. Hexokinase II integrates energy metabolism and cellular protection: akting on mitochondria and TORCing to autophagy. Cell Death Differ. 2015;22(2):248–57. doi:10.1038/cdd.2014.173.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang H, Chen S, Lu Z, Li B, Jiang T, Xuan M, Ye R, Liang H, Liu X, et al. SIRT1 regulated hexokinase-2 promoting glycolysis is involved in hydroquinone-enhanced malignant progression in human lymphoblastoid TK6 cells. Ecotox Environ Safe. 2022;241:113757. doi:10.1016/j.ecoenv.2022.113757.
   PubMed Web of Science ®Google Scholar
• Kozako T, Suzuki T, Yoshimitsu M, Arima N, Honda S, Soeda S. Anticancer agents targeted to sirtuins. Molecules. 2014;19(12):20295–313. doi:10.3390/molecules191220295.
   PubMed Web of Science ®Google Scholar
• Yan L, Zhao Q, Liu L, Jin N, Wang S, Zhan X. Expression of SIRT1 and survivin correlates with poor prognosis in esophageal squamous cell carcinoma. Medicine (Baltimore). 2020;99(34):e21645. doi:10.1097/MD.0000000000021645.
   PubMed Web of Science ®Google Scholar
• Otsuka R, Sakata H, Murakami K, Kano M, Endo S, Toyozumi T, Matsumoto Y, Suito H, Takahashi M, Sekino N, et al. SIRT1 expression is a promising prognostic biomarker in esophageal squamous cell carcinoma: a systematic review and meta-analysis. Cancer Diagn Prognosis. 2022;2(2):126–33. doi:10.21873/cdp.10086.
   PubMedGoogle Scholar
• Ma MC, Chiu TJ, Lu HI, Huang WT, Lo CM, Tien WY, Lan Y-C, Chen Y-Y, Chen C-H, Li S-H, et al. SIRT1 overexpression is an independent prognosticator for patients with esophageal squamous cell carcinoma. J Cardiothorac Surg. 2018;13(1):25. doi:10.1186/s13019-018-0718-5.
   PubMedGoogle Scholar
• Yang Z, Wan J, Ma L, Li Z, Yang R, Yang H, Li J, Zhou F, Ming L. Long non-coding RNA HOXC-AS1 exerts its oncogenic effects in esophageal squamous cell carcinoma by interaction with IGF2BP2 to stabilize SIRT1 expression. J Clin Lab Anal. 2023;37(1):e24801. doi:10.1002/jcla.24801.
   PubMed Web of Science ®Google Scholar
• Lin W, Qian J, Wang H, Ren L, Yang Y, Chen C, Chen X, Huang Y, Liu J, Xu N, et al. Cisplatin plus anti-PD-1 antibody enhanced treatment efficacy in advanced esophageal squamous cell carcinoma. Am J Cancer Res. 2022;12(2):451–68.
   PubMed Web of Science ®Google Scholar
• Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36. doi:10.1016/j.phrs.2016.01.001.
   PubMed Web of Science ®Google Scholar
• Nie C, Qin X, Li X, Tian B, Zhao Y, Jin Y, Li Y, Wang Q, Zeng D, Hong A, et al. CACNA2D3 enhances the chemosensitivity of esophageal squamous cell carcinoma to cisplatin via inducing Ca(2+)-mediated apoptosis and suppressing PI3K/Akt pathways. Front Oncol. 2019;9:185. doi:10.3389/fonc.2019.00185.
   PubMed Web of Science ®Google Scholar
• Zheng ZY, Yang PL, Li RY, Liu LX, Xu XE, Liao LD, Li X, Chu M-Y, Peng L, Huang Q-F, et al. STAT3β disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma. Cancer Lett. 2021;522:171–83. doi:10.1016/j.canlet.2021.09.035.
   PubMed Web of Science ®Google Scholar
• Bommer GT, Van Schaftingen E, Veiga-da-Cunha M. Metabolite repair enzymes control metabolic damage in glycolysis. Trends Biochem Sci. 2020;45(3):228–43. doi:10.1016/j.tibs.2019.07.004.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao M, Cui J, Wu X, Li Y, Wu W, Zhang X. Ochratoxin a induces reprogramming of glucose metabolism by switching energy metabolism from oxidative phosphorylation to glycolysis in human gastric epithelium GES-1 cells in vitro. Toxicol Lett. 2020;333:232–41. doi:10.1016/j.toxlet.2020.08.008.
   PubMed Web of Science ®Google Scholar
• Ancey PB, Contat C, Meylan E. Glucose transporters in cancer – from tumor cells to the tumor microenvironment. FEBS J. 2018;285(16):2926–43. doi:10.1111/febs.14577.
   PubMed Web of Science ®Google Scholar
• Koukourakis MI, Kalamida D, Mitrakas AG, Liousia M, Pouliliou S, Sivridis E, Giatromanolaki A. Metabolic cooperation between co-cultured lung cancer cells and lung fibroblasts. Lab Invest. 2017;97(11):1321–31. doi:10.1038/labinvest.2017.79.
   PubMed Web of Science ®Google Scholar